Table 2.

Validated hits from hSSPN-EGFP screen reveal enrichment of calcium channel blockers

Compound	Description
Felodipine	L-type Ca2 + channel blocker
GW5074	cRaf1 kinase inhibitor
Isoproterenol	Sympathomimetic amine acting on β-adrenoceptors
Isradipine	L-type Ca2 + channel blocker
Lacidipine	L-type Ca2 + channel blocker
Nandrolone	Anabolic-androgenic steroid
Nilvadipine	L-type Ca2 + channel blocker

The screen resulted in 13 initial hits, which were further validated with the hSSPN-EGFP reporter with an n = 24. The 7 validated hits included an overrepresented number of L-type calcium channel blockers